JP2002536404A - 炎症性腸疾患を治療するための好中球機能の刺激 - Google Patents
炎症性腸疾患を治療するための好中球機能の刺激Info
- Publication number
- JP2002536404A JP2002536404A JP2000598148A JP2000598148A JP2002536404A JP 2002536404 A JP2002536404 A JP 2002536404A JP 2000598148 A JP2000598148 A JP 2000598148A JP 2000598148 A JP2000598148 A JP 2000598148A JP 2002536404 A JP2002536404 A JP 2002536404A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- crohn
- patient
- stimulating factor
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000440 neutrophil Anatomy 0.000 title claims description 23
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract description 12
- 230000004936 stimulating effect Effects 0.000 title description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims abstract description 31
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 10
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims abstract description 8
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims abstract description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 64
- 206010016717 Fistula Diseases 0.000 claims description 29
- 239000000556 agonist Substances 0.000 claims description 28
- 230000003890 fistula Effects 0.000 claims description 28
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims description 26
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 claims description 12
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims description 12
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims description 12
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 9
- 208000002389 Pouchitis Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 230000005856 abnormality Effects 0.000 claims description 7
- 239000000816 peptidomimetic Substances 0.000 claims description 7
- 208000011476 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib Diseases 0.000 claims description 6
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 6
- 208000016361 genetic disease Diseases 0.000 claims description 6
- 208000005516 glycogen storage disease Ib Diseases 0.000 claims description 6
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 210000000813 small intestine Anatomy 0.000 claims description 6
- 229960002170 azathioprine Drugs 0.000 claims description 5
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 210000002429 large intestine Anatomy 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 206010048946 Anal abscess Diseases 0.000 claims 2
- 230000008378 epithelial damage Effects 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000017283 Bile Duct disease Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010015084 Episcleritis Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 208000028299 esophageal disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract description 3
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 35
- 230000009266 disease activity Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 206010009900 Colitis ulcerative Diseases 0.000 description 14
- 201000006704 Ulcerative Colitis Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000003442 weekly effect Effects 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 244000005709 gut microbiome Species 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229960000598 infliximab Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 206010002156 anal fistula Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 206010024378 leukocytosis Diseases 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 238000011268 retreatment Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010006002 Bone pain Diseases 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 206010025280 Lymphocytosis Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 208000036379 Sigmoiditis Diseases 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 208000026928 Turner syndrome Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000011882 arthroplasty Methods 0.000 description 2
- 229940072224 asacol Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 229940104799 dipentum Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 229940063148 rowasa Drugs 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 108010038379 sargramostim Proteins 0.000 description 2
- 229960002530 sargramostim Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002563 stool test Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000004315 EAST syndrome Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000002306 Eye Manifestations Diseases 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 208000017415 Functional neutrophil defect Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000033301 Ileal fistula Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940113720 aminosalicylate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 201000001546 cyclic hematopoiesis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010070560 lymphocyte proliferation potentiating factors Proteins 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 229950010676 nartograstim Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940072223 pentasa Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007460 surgical drainage Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 206010051250 ureteritis Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Studio Devices (AREA)
- Silicon Compounds (AREA)
- Treatment Of Sludge (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11984299P | 1999-02-12 | 1999-02-12 | |
| US60/119,842 | 1999-02-12 | ||
| PCT/US2000/003407 WO2000047195A1 (en) | 1999-02-12 | 2000-02-11 | Stimulating neutrophil function to treat inflammatory bowel disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005124264A Division JP2005225890A (ja) | 1999-02-12 | 2005-04-21 | 炎症性腸疾患を治療するための好中球機能の刺激 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002536404A true JP2002536404A (ja) | 2002-10-29 |
| JP2002536404A5 JP2002536404A5 (enExample) | 2006-02-09 |
Family
ID=22386711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000598148A Withdrawn JP2002536404A (ja) | 1999-02-12 | 2000-02-11 | 炎症性腸疾患を治療するための好中球機能の刺激 |
| JP2005124264A Pending JP2005225890A (ja) | 1999-02-12 | 2005-04-21 | 炎症性腸疾患を治療するための好中球機能の刺激 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005124264A Pending JP2005225890A (ja) | 1999-02-12 | 2005-04-21 | 炎症性腸疾患を治療するための好中球機能の刺激 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1150666B1 (enExample) |
| JP (2) | JP2002536404A (enExample) |
| AT (1) | ATE446767T1 (enExample) |
| AU (1) | AU764681C (enExample) |
| CA (1) | CA2367575A1 (enExample) |
| DE (1) | DE60043216D1 (enExample) |
| WO (1) | WO2000047195A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004100972A1 (ja) * | 2003-05-16 | 2004-11-25 | Kyowa Hakko Kogyo Co., Ltd. | 組織破壊を伴う疾患の予防及び／または治療剤 |
| WO2005082402A1 (ja) * | 2004-03-02 | 2005-09-09 | Hokkaido Technology Licensing Office Co., Ltd. | 臓器線維症予防・治療剤 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6500418B1 (en) | 1999-02-12 | 2002-12-31 | The Washington University | Stimulating neutrophil function to treat inflammatory bowel disease |
| WO2007134907A2 (en) * | 2006-05-18 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) * | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| NZ228031A (en) * | 1984-07-06 | 1991-12-23 | Sandoz Ltd | Primate gm-csf and method of extraction |
| ZA856108B (en) * | 1984-10-29 | 1986-10-29 | Immunex Corp | Cloning of human granulocyte-macrophage colony simulating factor gene |
| WO1988010310A1 (en) * | 1987-06-25 | 1988-12-29 | Immunex Corporation | Bovine granulocyte-macrophage colony stimulating factor |
| US4961926A (en) * | 1987-11-19 | 1990-10-09 | Sloan-Kettering Institute For Cancer Research | Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor |
| US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| WO1995009622A1 (en) * | 1993-10-06 | 1995-04-13 | Peptide Technology Limited | Polyunsaturated fatty acids and uses thereof |
| US5733915A (en) * | 1995-03-30 | 1998-03-31 | Glaxo Wellcome Inc. | Use of azathioprine to treat crohn's disease |
| US6037324A (en) * | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| WO1998043667A1 (en) * | 1997-04-01 | 1998-10-08 | Borody Thomas J | Methods and compositions for treating inflammatory bowel disease |
| DE19835080A1 (de) * | 1998-07-27 | 2000-02-03 | Doecke Wolf Dietrich | Mittel zur Behandlung des Krankheitsbildes Morbus Crohn |
-
2000
- 2000-02-11 AT AT00913421T patent/ATE446767T1/de not_active IP Right Cessation
- 2000-02-11 CA CA002367575A patent/CA2367575A1/en not_active Abandoned
- 2000-02-11 AU AU34871/00A patent/AU764681C/en not_active Ceased
- 2000-02-11 JP JP2000598148A patent/JP2002536404A/ja not_active Withdrawn
- 2000-02-11 DE DE60043216T patent/DE60043216D1/de not_active Expired - Lifetime
- 2000-02-11 EP EP00913421A patent/EP1150666B1/en not_active Expired - Lifetime
- 2000-02-11 WO PCT/US2000/003407 patent/WO2000047195A1/en not_active Ceased
-
2005
- 2005-04-21 JP JP2005124264A patent/JP2005225890A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004100972A1 (ja) * | 2003-05-16 | 2004-11-25 | Kyowa Hakko Kogyo Co., Ltd. | 組織破壊を伴う疾患の予防及び／または治療剤 |
| WO2005082402A1 (ja) * | 2004-03-02 | 2005-09-09 | Hokkaido Technology Licensing Office Co., Ltd. | 臓器線維症予防・治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3487100A (en) | 2000-08-29 |
| ATE446767T1 (de) | 2009-11-15 |
| AU764681C (en) | 2005-07-07 |
| EP1150666A1 (en) | 2001-11-07 |
| WO2000047195A1 (en) | 2000-08-17 |
| EP1150666B1 (en) | 2009-10-28 |
| DE60043216D1 (de) | 2009-12-10 |
| JP2005225890A (ja) | 2005-08-25 |
| CA2367575A1 (en) | 2000-08-17 |
| EP1150666A4 (en) | 2003-07-02 |
| AU764681B2 (en) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Real et al. | Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. | |
| Falk et al. | Treatment of progressive membranous glomerulopathy: A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone | |
| Hollender et al. | A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections | |
| Friton et al. | Long‐term effects of meloxicam in the treatment of respiratory disease in fattening cattle | |
| Ernstoff et al. | A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. | |
| US7407931B2 (en) | Method of treating Crohn's Disease using sargramostim | |
| Appel et al. | Acute interstitial nephritis due to amoxicillin therapy | |
| JP2002536404A (ja) | 炎症性腸疾患を治療するための好中球機能の刺激 | |
| AU2001279235A1 (en) | Stimulating neutrophil function to treat inflammatory bowel disease | |
| Yamamoto et al. | Granulocyte-colony stimulating factor-induced vasculitis successfully treated with short-term corticosteroid therapy: a case report | |
| Olson et al. | A unique presentation of extrapulmonary Legionella: rhabdomyolysis-induced acute renal failure and cerebellar dysfunction | |
| Valadao et al. | Evaluation of peritoneal fluid in horses with experimental endotoxemia | |
| Schoehl et al. | Severe acute respiratory distress syndrome during infliximab therapy in a patient with Crohn disease | |
| US20070141053A1 (en) | Treatment of inflammatory respiratory diseases | |
| JP2004537579A (ja) | 免疫調節化合物を用いる結核の処置 | |
| JP2023502015A (ja) | マルチターゲット型プロテインキナーゼ阻害剤の用途 | |
| Grad et al. | Listeria monocytogenes endophthalmitis–case report with a good visual outcome | |
| Furusawa et al. | Vesnarinone‐Induced Granulocytopenia: Incidence in Japan and Recommendations for Safety | |
| McCoy et al. | Gracie’s Gargantuan Gut | |
| Rivera et al. | Facial actinomycosis in a renal transplant patient | |
| CN119745851A (zh) | 氯硝柳胺的新用途 | |
| Cuthbertson et al. | Certain Preliminary Observations on the Treatment of Anæmia by Tryptophan and Histidine | |
| TW202543646A (zh) | 停止投予盧梭利替尼後以貝魯舒地爾治療慢性移植物抗宿主疾病之方法 | |
| Message et al. | Efficacy of intravenous ciclosporin in moderate corticoresistant ulcerative colitis | |
| KR19990028614A (ko) | 저투여량의 타입 ii 콜라겐에 의한 류마티스성 관절염의 치료방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040709 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040709 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20040709 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20040811 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041022 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050120 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050127 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20050421 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050525 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050811 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051104 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051207 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080627 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080702 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080729 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080826 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080829 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090415 |